Transcriptome sequencing of BCG-treated T1HG bladder cancer patients identifies an EMT-basal subgroup with immune suppressive characteristics at high risk of BCG failure

Abstract 614: Transcriptomic analysis of BCG-treated T1HG bladder cancer patients identifies an EMT-basal subgroup with immune suppressive characteristics at high risk of BCG-failure

10.1158/1538-7445.am2021-614 ◽

2021 ◽

Author(s):

Florus C. De Jong ◽

Teemu D. Laajala ◽

Robert F. Hoedemaeker ◽

Sébastien Rinaldetti ◽

Jolien T. Mensink ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Transcriptomic Analysis ◽

Bcg Failure ◽

Basal Subgroup

PD-L1 expression does not predict BCG-failure in a large cohort of high-risk non-muscle invasive bladder cancer patients

European Urology Open Science ◽

10.1016/s2666-1683(20)33260-2 ◽

2020 ◽

Vol 19 ◽

pp. e1013

Author(s):

F.C. De Jong ◽

R.F. Hoedemaeker ◽

A.M. Van Der Made ◽

V. Kvikstad ◽

T.P.P. Van Den Bosch ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Large Cohort ◽

Invasive Bladder Cancer ◽

Bcg Failure ◽

Abstract B06: Pathologic T1 substaging improves the identification of high-risk non-muscle invasive bladder cancer patients at risk of BCG failure

10.1158/1557-3265.bladder19-b06 ◽

2020 ◽

Author(s):

Florus C. de Jong ◽

Robert F. Hoedemaeker ◽

Jolien T.M. Mensink ◽

Vebjørn Kvikstad ◽

Egbert R. Boevé ◽

...

Keyword(s):

At Risk ◽

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Invasive Bladder Cancer ◽

Patients At Risk ◽

Bcg Failure ◽

Long-Term Outcomes and Costs Among BCG-treated High-Risk Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2020.10.041 ◽

2020 ◽

Vol 38 (12) ◽

pp. 902

Author(s):

SB Williams ◽

LE Howard ◽

ML Foster ◽

Z Klaassen ◽

H Li ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Equal Access ◽

Invasive Bladder Cancer ◽

Long Term Outcomes ◽

Definitions of BCG-failure (EAU) vs BCG-unresponsive (FDA) in high-risk non-muscle invasive bladder cancer: A comparison of patient outcome

European Urology Open Science ◽

10.1016/s2666-1683(20)33370-x ◽

2020 ◽

Vol 19 ◽

pp. e1171

Author(s):

F.C. De Jong ◽

R.F. Hoedemaeker ◽

V. Kvikstad ◽

J.T.M. Mensink ◽

E.R. Boevé ◽

...

Keyword(s):

Patient Outcome ◽

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Bcg Failure ◽

942 Should second TUR be performed in the first 2–6 weeks after the initial TUR necessarily in high risk non-muscle invasive bladder cancer patients receiving maintanance BCG? Multicenter trial of Turkish Society of Urooncology

European Urology Supplements ◽

10.1016/s1569-9056(15)60930-7 ◽

2015 ◽

Vol 14 (2) ◽

pp. e942-e942a

Author(s):

S.B. Baltacı ◽

M. Bozlu ◽

A. Yıldırm ◽

M.I. Gökce ◽

I. Tınay ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Multicenter Trial ◽

Invasive Bladder Cancer ◽

Second Tur ◽

Muscle Invasive ◽

Turkish Society

PCN233 TREATMENT PATTERNS IN HIGH-RISK, BACILLE CALMETTE-GUÉRIN UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS: A SYSTEMATIC LITERATURE REVIEW

Value in Health ◽

10.1016/j.jval.2020.04.1704 ◽

2020 ◽

Vol 23 ◽

pp. S64

Author(s):

E. Broughton ◽

D. Chun ◽

K. Gooden ◽

K. Hofer ◽

M.S. Fazeli

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Literature Review ◽

Cancer Patients ◽

Systematic Literature Review ◽

Treatment Patterns ◽

Invasive Bladder Cancer ◽

Bacille Calmette Guerin ◽

PD19-07 ONE-YEAR FOLLOW-UP RESULTS AFTER SEQUENTIAL INTRAVESICAL BACILLUS CALMETTE-GUÉRIN AND DEVICE-ASSISTED CHEMO-HYPERTHERMIA (MITOMYCIN C DELIVERED BY THE COMBAT BRS SYSTEM) FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS...A BACILLUS CALMETTE-GUÉRIN-SPARING STRATEGY

The Journal of Urology ◽

10.1016/j.juro.2017.02.880 ◽

2017 ◽

Vol 197 (4S) ◽

Cited By ~ 1

Author(s):

TR Leyshon Griffiths ◽

William JF Green ◽

Peter T Grice ◽

Jonathan C Goddard ◽

Roger C Kockelbergh

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Mitomycin C ◽

Invasive Bladder Cancer ◽

Bacillus Calmette Guerin ◽

Muscle Invasive ◽

One Year

Management of BCG failure in high-risk non-muscle-invasive bladder cancer

10.18591/bjuik.0677 ◽

2018 ◽

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Bcg Failure ◽

A phase III randomized controlled trial of adjuvant chemoradiotherapy (CRT) and postoperative radiotherapy (PORT) versus PORT alone in high risk bladder cancer patients

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.4585 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 4585-4585

Author(s):

M. S. Zaghloul ◽

H. M. Khaled ◽

M. Loutayef ◽

M. S. Nazmy ◽

H. William

Keyword(s):

Bladder Cancer ◽

Randomized Controlled Trial ◽

High Risk ◽

Cancer Patients ◽

Controlled Trial ◽

Postoperative Radiotherapy ◽

Phase Iii ◽

Adjuvant Chemoradiotherapy ◽

Randomized Controlled